Last reviewed · How we verify
First line high-dose amoxicillin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
First line high-dose amoxicillin (First line high-dose amoxicillin) — Second Affiliated Hospital, School of Medicine, Zhejiang University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| First line high-dose amoxicillin TARGET | First line high-dose amoxicillin | Second Affiliated Hospital, School of Medicine, Zhejiang University | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- First line high-dose amoxicillin CI watch — RSS
- First line high-dose amoxicillin CI watch — Atom
- First line high-dose amoxicillin CI watch — JSON
- First line high-dose amoxicillin alone — RSS
Cite this brief
Drug Landscape (2026). First line high-dose amoxicillin — Competitive Intelligence Brief. https://druglandscape.com/ci/first-line-high-dose-amoxicillin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing